`
`Mylan Completes Acquisition of Meda - Aug 5, 2016
`
`Mylan Completes Acquisition of Meda
`
`HERTFORDSHIRE, England and PITTSBURGH, Aug. 5, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ,
`TASE: MYL) today announced that it has completed the settlement of its recommended public offer to the
`shareholders of Meda Aktiebolag (publ.) to tender all their shares in Meda to Mylan (the "Offer"). As
`previously announced, the Offer was accepted by shareholders holding approximately 94% of the total
`number of outstanding shares and votes in Meda, as of July 29, 2016. Upon the completion and settlement
`of the Offer, Mylan acquired each of these shares in accordance with the terms of the Offer. The Offer was
`initially announced on Feb. 10, 2016 and it was declared unconditional on Aug. 2, 2016. The acceptance
`period expired on July 29, 2016 and will not be extended.
`
`Mylan Chairman Robert Coury commented, "We are very
`pleased to have received the overwhelming shareholder support
`required to complete our acquisition of Meda. Mylan continues
`to differentiate itself among the world's pharmaceutical
`companies in terms of our unique profile and growth trajectory.
`The addition of Meda will only further add to our existing
`leadership position within our space and continue to create
`significant value for our shareholders and other stakeholders. On behalf of Mylan's entire board of
`directors, we welcome our new Mylan shareholders and look forward to them sharing in the anticipated
`future success of our combined company."
`
`Mylan CEO Heather Bresch continued, "The addition of Meda builds on everything we have put in place
`around the world, creating even greater scale, breadth and diversity across products, geographies and
`sales channels. As a result, our R&D and manufacturing platform is unmatched, and we now have a more
`powerful global commercial infrastructure across developed and emerging markets and branded, generic
`and over-the-counter products. This transaction also is extremely compelling financially, providing
`significant accretion to Mylan's adjusted earnings per share, the opportunity for substantial synergies and
`further acceleration of our growth. Importantly, I would like to welcome Meda's talented and dedicated
`workforce to the Mylan family, and I look forward to their contributions as we strive to deliver better health
`for a better world."
`
`Mylan President Rajiv Malik added, "With the addition of Meda, Mylan now has six $1 billion therapeutic
`franchises, and through our enhanced scale and expanded commercial capabilities, we see significant
`opportunities to further distinguish Mylan among our customers and patients. Allergy/respiratory, pain/CNS
`and dermatology – recently bolstered by our acquisition of the Renaissance topicals business – represent
`just a few of the exciting areas where we expect to create additional value from our combined portfolio,
`pipeline and capabilities. Meda also opens up a number of new opportunities for us, such as significantly
`expanding our over-the-counter presence into a $1 billion business. Additionally, Meda accelerates our
`expansion in attractive emerging markets, such as China, Southeast Asia, Russia and the Middle East,
`and provides us opportunities to maximize our efficient, high quality operating platform and broad product
`
`newsroom.mylan.com/2016-08-05-Mylan-Completes-Acquisition-of-Meda
`
`1/4
`
`CIPLA LTD. EXHIBIT 2012 PAGE 1
`
`
`
`Mylan Completes Acquisition of Meda - Aug 5, 2016
`4/30/2020
`portfolio. I too would like to extend a warm welcome to the Meda team and am excited to begin integrating
`our businesses and bringing together the best from both of our organizations."
`
`Meda is now a controlled subsidiary of Mylan. Mylan intends to initiate compulsory acquisition proceedings
`for the remaining shares in Meda in accordance with the Swedish Companies Act (Sw. aktiebolagslagen
`(2005:551)) and has acted to have the Meda shares delisted from Nasdaq Stockholm.
`
`Mylan discloses the information provided herein pursuant to Nasdaq Stockholm's Takeover Rules (the
`"Takeover Rules"). The information was submitted for publication on Aug. 5, 2016, 15:00 CET.
`
`Forward-Looking Statements
`
`This communication contains "forward-looking statements." Such forward-looking statements may include,
`without limitation, statements about the acquisition of Meda by Mylan (the "Meda Transaction"), the Offer,
`the benefits and synergies of the Meda Transaction, future opportunities for Mylan, Meda, or the combined
`company and products and any other statements regarding Mylan's, Meda's or the combined company's
`future operations, anticipated business levels, future earnings, planned activities, anticipated growth,
`market opportunities, strategies, competition, and other expectations and targets for future periods. These
`may often be identified by the use of words such as "will," "may," "could," "should," "would," "project,"
`"believe," "anticipate," "expect," "plan," "estimate," "forecast," "potential," "intend," "continue," "target" and
`variations of these words or comparable words. Because forward-looking statements inherently involve
`risks and uncertainties, actual future results may differ materially from those expressed or implied by such
`forward-looking statements. Factors that could cause or contribute to such differences include, but are not
`limited to: uncertainties related to the Meda Transaction; the ability to meet expectations regarding the
`accounting and tax treatments of Mylan's acquisition (the "EPD Transaction") of Mylan Inc. and Abbott
`Laboratories' non-U.S. developed markets specialty and branded generics business (the "EPD Business")
`and the Meda Transaction; changes in relevant tax and other laws, including but not limited to changes in
`the U.S. tax code and healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the
`integration of the EPD Business and Meda being more difficult, time-consuming, or costly than expected;
`operating costs, customer loss, and business disruption (including, without limitation, difficulties in
`maintaining relationships with employees, customers, clients, or suppliers) being greater than expected
`following the EPD Transaction and the Meda Transaction; the retention of certain key employees of the
`EPD Business and Meda being difficult; the possibility that Mylan may be unable to achieve expected
`synergies and operating efficiencies in connection with the EPD Transaction and the Meda Transaction
`within the expected time-frames or at all and to successfully integrate the EPD Business and Meda;
`expected or targeted future financial and operating performance and results; the capacity to bring new
`products to market, including but not limited to where Mylan uses its business judgment and decides to
`manufacture, market, and/or sell products, directly or through third parties, notwithstanding the fact that
`allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an "at-risk launch");
`any regulatory, legal, or other impediments to Mylan's ability to bring new products to market; success of
`clinical trials and Mylan's ability to execute on new product opportunities; any changes in or difficulties with
`our inventory of, and our ability to manufacture and distribute, the EpiPen® Auto-Injector to meet
`anticipated demand; the scope, timing, and outcome of any ongoing legal proceedings and the impact of
`any such proceedings on financial condition, results of operations, and/or cash flows; the ability to protect
`intellectual property and preserve intellectual property rights; the effect of any changes in customer and
`supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel;
`changes in third-party relationships; the impact of competition; changes in the economic and financial
`conditions of the businesses of Mylan, Meda or the combined company; the inherent challenges, risks, and
`costs in identifying, acquiring, and integrating complementary or strategic acquisitions of other companies,
`products or assets and in achieving anticipated synergies; uncertainties and matters beyond the control of
`newsroom.mylan.com/2016-08-05-Mylan-Completes-Acquisition-of-Meda
`
`2/4
`
`CIPLA LTD. EXHIBIT 2012 PAGE 2
`
`
`
`Mylan Completes Acquisition of Meda - Aug 5, 2016
`4/30/2020
`management; and inherent uncertainties involved in the estimates and judgments used in the preparation
`of financial statements, and the providing of estimates of financial measures, in accordance with
`accounting principles generally accepted in the United States and related standards or on an adjusted
`basis. For more detailed information on the risks and uncertainties associated with Mylan's business
`activities, see the risks described in Mylan's Annual Report on Form 10-K for the year ended December
`31, 2015, as amended, its Quarterly Report on Form 10-Q for the three months ended March 31, 2016 and
`its other filings with the SEC. These risks and uncertainties also include those risks and uncertainties that
`are discussed in the Offer Document that was published on June 16, 2016, the Registration Statement
`which was declared effective on June 16, 2016 and the EU Prospectus that was published on June 16,
`2016. You can access Mylan's filings with the SEC through the SEC website at www.sec.gov, and Mylan
`strongly encourages you to do so. Mylan undertakes no obligation to update any statements herein for
`revisions or changes after the date of this communication, except as required by law.
`
`Important Notice
`This communication has been published in Swedish and English. In the event of any discrepancy in
`content between the language versions, the Swedish version shall prevail.
`
`About Mylan
`Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working
`together around the world to provide 7 billion people access to high quality medicine, we innovate to
`satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and
`impact the future through passionate global leadership. We offer a growing portfolio of more than 2,700
`generic and branded pharmaceuticals, including antiretroviral therapies on which approximately 50% of
`people being treated for HIV/AIDS in the developing world depend. We market our products in more than
`165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities,
`and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our
`more than 40,000-strong workforce is dedicated to creating better health for a better world, one person at
`a time. Learn more at mylan.com.
`
`Logo - http://photos.prnewswire.com/prnh/20140423/77793
`
`
`
`SOURCE Mylan N.V.
`
`For further information: For further information, please contact: Media: Nina Devlin, Tel. +1 (724) 514-1968,
`Nina.Devlin@mylan.com; Investors: Kris King, Tel. +1 (724) 514-1813, Kris.King@mylanlabs.com
`
`Share
`
`Contact Mylan Privacy Shield Policy Privacy Statement
`Site Map California Supply Chains Act
`
`Terms and Conditions
`
`Follow Us
`
`©2020 Mylan N.V. All rights reserved.
`
`newsroom.mylan.com/2016-08-05-Mylan-Completes-Acquisition-of-Meda
`
`3/4
`
`CIPLA LTD. EXHIBIT 2012 PAGE 3
`
`
`
`Mylan Completes Acquisition of Meda - Aug 5, 2016
`4/30/2020
`The Mylan logo is a registered trademark of Mylan Inc.
`
`newsroom.mylan.com/2016-08-05-Mylan-Completes-Acquisition-of-Meda
`
`4/4
`
`CIPLA LTD. EXHIBIT 2012 PAGE 4
`
`